ReviewStem cells translational medicine2021
Current concepts on endothelial stem cells definition, location, and markers.
Review in Stem cells translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 65 citations in OpenAlex.
- CD157Stem cell reports · 2026Article
- Review
- The role of endothelial colony forming cells in the treatment of limb ischaemia: challenges in clinical translation.Stem cells translational medicine · 2026Review
- Role of stem cells in ocular diseases: Progress and challenges.Journal of biomedical research · 2026Article
- Aqueous humour extracellular vesicle membrane protein profiling reveals pathological features of refractory macular edema.Frontiers in cell and developmental biology · 2026Article
- Old World alphaviruses use distinct mechanisms to infect brain microvascular endothelial cells for neuroinvasion.Cell reports · 2025Article
- Stem cell therapies in the clinic.Bioengineering & translational medicine · 2025Review
- Cyclic nucleotide phosphodiesterases as drug targets.Pharmacological reviews · 2025Review
- Single-cell transcriptomics of clinical grade adipose-derived regenerative cells reveals consistency between donors independent of gender and BMI.Stem cell research & therapy · 2025Article
- SHP099-containing multi-targeting hydrogel promotes rapid skin reconstruction through modulating a variety of cells.Frontiers in bioengineering and biotechnology · 2025Article
- The vascular microenvironment and its stem cells regulate vascular homeostasis.Frontiers in cell and developmental biology · 2025Review
- Exosomes: the future of acellular nanotherapeutics in regenerative vascularization.Frontiers in bioengineering and biotechnology · 2025Review
- Extracellular vesicles derived from endothelial progenitor cells modified by Houshiheisan promote angiogenesis and attenuate cerebral ischemic injury via miR-126/PIK3R2.Scientific reports · 2024Article
- Blood-generating heart-forming organoids recapitulate co-development of the human haematopoietic system and the embryonic heart.Nature cell biology · 2024Article
- Identification of CD141Stem cell research & therapy · 2024Article
- The Use of Autologous Cell Therapy in Diabetic Patients with Chronic Limb-Threatening Ischemia.International journal of molecular sciences · 2024Review
- Responses of Endothelial Progenitor Cells to Chronic and Acute Physical Activity in Healthy Individuals.International journal of molecular sciences · 2024Review
- Clinical applications of stem cell-derived exosomes.Signal transduction and targeted therapy · 2024Review
- Enhancing endothelial colony-forming cells for treating diabetic vascular complications: challenges and clinical prospects.Frontiers in endocrinology · 2024Review
- Analysis of endothelial progenitor cell subtypes as clinical biomarkers for elderly patients with ischaemic stroke.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Ischemic vascular disease is a major cause of mortality and morbidity worldwide, and regeneration of blood vessels in perfusion-deficient tissues is a worthwhile therapeutic goal. The idea of delivering endothelial stem/progenitor cells to repair damaged vasculature, reperfuse hypoxic tissue, prevent cell death, and consequently diminish tissue inflammation and fibrosis has a strong scientific basis and clinical value. Various labs have proposed endothelial stem/progenitor cell candidates. This has created confusion, as there are profound differences between these cell definitions based on isolation methodology, characterization, and reparative biology. Here, a stricter definition based on stem cell biology principles is proposed. Although preclinical studies have often been promising, results from clinical trials have been highly contradictory and served to highlight multiple challenges associated with disappointing therapeutic benefit. This article reviews recent accomplishments in the field and discusses current difficulties when developing endothelial stem cell therapies. Emerging evidence that disputes the classic view of the bone marrow as the source for these cells and supports the vascular wall as the niche for these tissue-resident endothelial stem cells is considered. In addition, novel markers to identify endothelial stem cells, including CD157, EPCR, and CD31
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.